

**[Notice] Allplex™ 2019-nCoV assay has received Emergency Use****Authorization by Korean Center for Disease Control and Prevention**

Dear our valued customer,

The 2019 Novel Coronavirus named as COVID-19, was first identified in Wuhan City, Hubei Province, China in December of 2019, causes respiratory illness in people. On 30 January 2020, World Health Organization(WHO) declared the outbreak of COVID-19 as a global health emergency. Since the reporting of full genome of COVID-19 by Chinese Center for Disease Control and Prevention through the GISAID Initiative, several target genes have been announced to screen and identify the COVID-19 infected cases.

We, Seegene, Inc., checked the cross reactivity between Allplex™ Respiratory Panel 3 assay which detects Coronavirus NL63, Coronavirus 229E, Coronavirus OC43 does not have cross-reactivity with COVID-19. Thereafter, we have designed the new product, Allplex™ 2019-nCoV assay, to selectively diagnose the infection by novel coronavirus under the recommended protocol by WHO collaboration lab in Berlin and China CDC.

Allplex™ 2019-nCoV assay had received CE-IVD on Feb 10<sup>th</sup> and Emergency Use Authorization from the Korea Centers for Disease Control and Prevention on Feb 12<sup>th</sup>.

If you have any questions about the Allplex™ 2019-nCoV assay or if you have customer, wants product for their suspected patients, please contact your regional manager.

We are willing to answer to your question and help for you and your customers.

---



---

**Eugene Kim , Ph.D.**

Executive Director of Marketing Department  
Seegene, Inc.